GlaxoSmithKline will change incentives for sales representatives in some countries as the British drugmaker looks to retain talent.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
The Allen Institute for Cell Science launched the Integrated Mitotic Stem Cell, a new tool that visualizes mitosis.
Amgen Inc.’s drug discovery position will be boosted after agreeing to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).
Germany-based Evotec SE followed up a string of collaborations with pharma companies with the $90 million acquisition of Bill & Melinda Gates Foundation-backed Just Biotherapeutics Inc.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi, and six major health systems.
Shares of North Carolina-based BioCryst Pharmaceuticals were down more than 53 percent after the company released data from a Phase III trial that underwhelmed analysts.
Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10 percent hit to annual net sales of the company’s gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as much as 34 percent.
U.S. drugmaker Merck & Co. Inc. agreed to buy Peloton Therapeutics Inc. for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.
Vaunted immunotherapy pioneers from the Dana-Farber Cancer Institute won a key court case that could be worth billions of dollars.
The U.S. Supreme Court on Monday handed a victory to Merck & Co. – at least for now – by throwing out a lower court ruling that had revived hundreds of lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking the osteoporosis drug Fosamax.